We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is CorMedix (CRMD - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CorMedix is a member of the Medical sector. This group includes 1020 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CorMedix is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CRMD's full-year earnings has moved 20.7% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, CRMD has moved about 126.1% on a year-to-date basis. At the same time, Medical stocks have lost an average of 3.5%. This means that CorMedix is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is ResMed (RMD - Free Report) . The stock has returned 36% year-to-date.
In ResMed's case, the consensus EPS estimate for the current year increased 4.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, CorMedix belongs to the Medical - Biomedical and Genetics industry, a group that includes 501 individual stocks and currently sits at #61 in the Zacks Industry Rank. On average, stocks in this group have lost 11% this year, meaning that CRMD is performing better in terms of year-to-date returns.
In contrast, ResMed falls under the Medical - Products industry. Currently, this industry has 87 stocks and is ranked #127. Since the beginning of the year, the industry has moved +11.8%.
Investors with an interest in Medical stocks should continue to track CorMedix and ResMed. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is CorMedix (CRMD - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CorMedix is a member of the Medical sector. This group includes 1020 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CorMedix is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CRMD's full-year earnings has moved 20.7% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, CRMD has moved about 126.1% on a year-to-date basis. At the same time, Medical stocks have lost an average of 3.5%. This means that CorMedix is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is ResMed (RMD - Free Report) . The stock has returned 36% year-to-date.
In ResMed's case, the consensus EPS estimate for the current year increased 4.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, CorMedix belongs to the Medical - Biomedical and Genetics industry, a group that includes 501 individual stocks and currently sits at #61 in the Zacks Industry Rank. On average, stocks in this group have lost 11% this year, meaning that CRMD is performing better in terms of year-to-date returns.
In contrast, ResMed falls under the Medical - Products industry. Currently, this industry has 87 stocks and is ranked #127. Since the beginning of the year, the industry has moved +11.8%.
Investors with an interest in Medical stocks should continue to track CorMedix and ResMed. These stocks will be looking to continue their solid performance.